Ying Hou1, Kai Shao2, Yaping Yan3, Tingjun Dai1, Wei Li1, Yuying Zhao1, Duoling Li1, Jian-Qiang Lu4, Gary L Norman5, Chuanzhu Yan6,7,8. 1. Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107 West Wenhua Road, Jinan, Shandong, China. 2. Department of Central Laboratory and Mitochondrial Medicine Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China. 3. Key Laboratory of the Ministry of Education for Medicinal Resources and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Development of Endangered Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xian, China. 4. Neuropathology Section, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 5. Inova Diagnostics, San Diego, CA, USA. 6. Research Institute of Neuromuscular and Neurodegenerative Diseases and Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, No. 107 West Wenhua Road, Jinan, Shandong, China. chuanzhuyan@163.com. 7. Department of Central Laboratory and Mitochondrial Medicine Laboratory, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China. chuanzhuyan@163.com. 8. Brain Science Research Institute, Shandong University, Jinan, China. chuanzhuyan@163.com.
Abstract
OBJECTIVE: To characterize the clinical and pathological features of anti-HMGCR myopathy. METHODS: The presence of anti-HMGCR antibody in the serum of 227 patients with idiopathic inflammatory myopathy (IIM) and 100 healthy control individuals was assessed by ELISA. All ELISA positive samples were retested by indirect immunofluorescence assay (IIFA) on HEK293 cells. The clinical findings, muscle pathological features, and treatment outcomes of patients with anti-HMGCR myopathy, along with comparisons between anti-HMGCR myopathy with and without dermatomyositis (DM)-like skin rashes, and among MSA-based subgroups were analyzed. RESULTS: We established an optimized ELISA cutoff for anti-HMGCR antibody positivity as ≥ 5.28 U. The overall concordance between ELISA and IIFA was 96.83%. Twenty-one out of 227 IIM patients were anti-HMGCR-positive by both assays. Of these 21 patients, 9 had DM-like skin rashes, and 16 showed remarkable muscle inflammation; 5 patients were juvenile-onset, and 2 received statin treatment. The muscle biopsies from these patients demonstrated variable muscle necrosis and T cell infiltration. Most anti-HMGCR-positive patients achieved favorable outcomes following prednisone and additional immunotherapies. The anti-HMGCR myopathy patients with DM-like rashes, compared to those without DM-like rashes, were younger and had a shorter disease duration. CONCLUSIONS: Optimization of cutoff of anti-HMGCR antibody assays with confirmation by alternative assays can result in higher sensitivity and specificity. DM-like skin rashes and lymphocytic infiltrates were not rare in patients with anti-HMGCR myopathy. These findings suggest that while anti-HMGCR myopathy may overlap with DM-like rash, it is pathologically different from classic DM, and should be considered a distinct subgroup of IIM.
OBJECTIVE: To characterize the clinical and pathological features of anti-HMGCR myopathy. METHODS: The presence of anti-HMGCR antibody in the serum of 227 patients with idiopathic inflammatory myopathy (IIM) and 100 healthy control individuals was assessed by ELISA. All ELISA positive samples were retested by indirect immunofluorescence assay (IIFA) on HEK293 cells. The clinical findings, muscle pathological features, and treatment outcomes of patients with anti-HMGCR myopathy, along with comparisons between anti-HMGCR myopathy with and without dermatomyositis (DM)-like skin rashes, and among MSA-based subgroups were analyzed. RESULTS: We established an optimized ELISA cutoff for anti-HMGCR antibody positivity as ≥ 5.28 U. The overall concordance between ELISA and IIFA was 96.83%. Twenty-one out of 227 IIM patients were anti-HMGCR-positive by both assays. Of these 21 patients, 9 had DM-like skin rashes, and 16 showed remarkable muscle inflammation; 5 patients were juvenile-onset, and 2 received statin treatment. The muscle biopsies from these patients demonstrated variable muscle necrosis and T cell infiltration. Most anti-HMGCR-positive patients achieved favorable outcomes following prednisone and additional immunotherapies. The anti-HMGCR myopathy patients with DM-like rashes, compared to those without DM-like rashes, were younger and had a shorter disease duration. CONCLUSIONS: Optimization of cutoff of anti-HMGCR antibody assays with confirmation by alternative assays can result in higher sensitivity and specificity. DM-like skin rashes and lymphocytic infiltrates were not rare in patients with anti-HMGCR myopathy. These findings suggest that while anti-HMGCR myopathy may overlap with DM-like rash, it is pathologically different from classic DM, and should be considered a distinct subgroup of IIM.
Authors: Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes Journal: Neuromuscul Disord Date: 2004-05 Impact factor: 4.296
Authors: Lucile Musset; Yves Allenbach; Olivier Benveniste; Olivier Boyer; Xavier Bossuyt; Chelsea Bentow; Joe Phillips; Andrew Mammen; Philip Van Damme; René Westhovens; Anna Ghirardello; Andrea Doria; May Y Choi; Marvin J Fritzler; Heinrike Schmeling; Yoshinao Muro; Ignacio García-De La Torre; Miguel A Ortiz-Villalvazo; Nicola Bizzaro; Maria Infantino; Tiziana Imbastaro; Qinglin Peng; Guochun Wang; Jiří Vencovský; Martin Klein; Olga Krystufkova; Franco Franceschini; Micaela Fredi; Sophie Hue; Thibaut Belmondo; Katalin Danko; Michael Mahler Journal: Autoimmun Rev Date: 2016-08-01 Impact factor: 9.754
Authors: Andrew L Mammen; Tae Chung; Lisa Christopher-Stine; Paul Rosen; Antony Rosen; Kimberly R Doering; Livia A Casciola-Rosen Journal: Arthritis Rheum Date: 2011-03
Authors: Albert Selva-O'Callaghan; Iago Pinal-Fernandez; Ernesto Trallero-Araguás; José César Milisenda; Josep Maria Grau-Junyent; Andrew L Mammen Journal: Lancet Neurol Date: 2018-09 Impact factor: 44.182